Dynamic quotes: Off
|
Company Description (as filed with the SEC)
We engineer enzymes for pharmaceutical, biofuel and chemical production. Our proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing. We have commercialized our technology and products in the pharmaceuticals market, which is our primary business focus. There are currently over 50 pharmaceutical firms using our technology, products and services in their manufacturing process development, including in the production of some of the world's bestselling and fastest growing drugs. We are a developing our CodeXyme® cellulase enzymes to convert non-food plant material, or cellulosic biomass, into affordable sugars, which can then be converted into renewable fuels and chemicals. We are also developing our own manufacturing process for CodeXol® detergent alcohols, which are bio-based chemicals. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.84 |
| Quarterly EPS Est: | -0.28 |
| PEG Ratio: | .00 |
|
Mean Recommendation: View Summary / View All |
3 |
Data is provided by Zacks Investment Research
